Angiotech announces results for the fourth quarter ended Decembe...(ne in Brussels Belgium on March 18 2008....)
| HOME >> BIOLOGY >> TECHNOLOGY |
ne in Brussels, Belgium on March 18, 2008. Should our
5-FU CVC product candidate receive FDA marketing clearance, we would
anticipate commencing commercial launch activities in the second half
of 2008.
- Quill(TM) SRS: In October 2007 we received CE Mark approval to begin
marketing the Quill(TM) Self-Retaining System (SRS) MONODERM(TM)
product line in Europe. In addition, we exceeded our stated goal of
100 Quill(TM) SRS hospital accounts by the end of 2007, and expect to
expand the number of Quill(TM) SRS SKUs available for sale to our
customers in 2008.
- Vascular Wrap(TM): Enrolment in our AV access human clinical trials
in the U.S. and Europe continues and we currently expect to complete
enrolment in these studies around the end of the first half of 2008.
- Stem Cell Therapies: In December 2007 our partner, Athersys, Inc.
received authorization from the U.S. FDA to begin a Phase I clinical
trial evaluating the safety of MultiStem(R) in the treatment of acute
myocardial infarction. We have an agreement with Athersys to co-
develop and commercialize MultiStem(R), Athersys' non-embryonic stem
cell platform technology, for use in the indications of acute
myocardial infarction and peripheral vascular disease.
- TAXUS(R) paclitaxel-eluting stent systems: In December 2007 our
partner, BSC, announced that the TAXUS(R) Liberte(TM) paclitaxel-
eluting coronary stent system received European CE Mark approval for
use in diabetic patients.
2008 Outlook
Our financial outlook for the upcoming fiscal year ending December 31,
2008 is presented below. Several material factors and assumptions were used
to derive our 2008 outlook, including: (i) estimates of medical procedure
and patient population growth rates for the various end markets relating
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |